Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic Value of Restaging [<sup>18</sup>F]FDG PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [<sup>177</sup>Lu]Lu-PSMA-617 Therapy.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Predicting immunotherapy benefit in leiomyosarcoma through active chromatin cfDNA profiling.

NPJ precision oncology·2026
Same author

[<sup>177</sup>Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study.

The Lancet. Oncology·2026
Same author

A practical toolkit with recommendations for analysing and visualising patient-reported outcomes in early phase dose-finding oncology trials (OPTIMISE-AR).

The Lancet. Oncology·2026
Same author

Clinical validation of a tissue-agnostic genome-wide methylome enrichment assay to monitor response to pembrolizumab.

NPJ precision oncology·2026
Same author

International Consensus-Driven Recommendations for Patient-Reported Outcome Research Objectives in Early Phase Dose-Finding Oncology Trials: OPTIMISE-ROR.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Related Experiment Video

Updated: Jun 21, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Prostate Cancer Working Group 4 Recap.

Aravind S Ravi Kumar1, Aaron R Hansen2

  • 1Integrated Theranostics Centre, Department of Radiology, Princess Alexandra Hospital, Brisbane, Australia; School of Medicine, University of Queensland, Queensland, Australia.

European Urology Focus
|June 19, 2026
PubMed
Summary
This summary is machine-generated.

The Prostate Cancer Clinical Trials Working Group (PCWG) updated recommendations (PCWG4) enhance prostate cancer trials. New guidelines focus on patient-centered outcomes, advanced biomarkers, and imaging like PSMA PET/CT for better trial design and interpretation.

Keywords:
Clinical trialsPCWG4PSMAProstate cancer

More Related Videos

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization
07:34

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization

Published on: November 17, 2023

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Related Experiment Videos

Last Updated: Jun 21, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization
07:34

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization

Published on: November 17, 2023

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Area of Science:

  • Oncology
  • Clinical Trials Methodology

Background:

  • The Prostate Cancer Clinical Trials Working Group (PCWG) has historically guided prostate cancer trial design.
  • Recent advancements in molecular diagnostics, imaging, and therapies necessitate an updated framework.

Purpose of the Study:

  • To summarize key updates in the PCWG4 recommendations.
  • To highlight the implications of these changes for contemporary prostate cancer clinical trial design and interpretation.

Main Methods:

  • Review and synthesis of the PCWG4 recommendations.
  • Focus on shifts in terminology, endpoints, biomarker integration, and imaging protocols.

Main Results:

  • PCWG4 introduces patient-centered terminology and endpoints.
  • Incorporation of molecular and imaging biomarkers (e.g., PSMA PET/CT) for eligibility and response assessment.
  • Revised definitions of radiographic progression and emphasis on patient-reported outcomes and "no longer clinically benefitting" concept.

Conclusions:

  • PCWG4 represents a significant evolution in prostate cancer clinical trial guidelines.
  • The updated framework aims to improve trial relevance, efficiency, and patient-centricity.
  • These changes will impact the design and interpretation of future prostate cancer studies.